Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt 558.01
NAS:ACHN's Cash-to-Debt is ranked higher than
56% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. NAS:ACHN: 558.01 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:ACHN' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.1  Med: 117.7 Max: No Debt
Current: 558.01
Equity-to-Asset 0.97
NAS:ACHN's Equity-to-Asset is ranked higher than
97% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:ACHN: 0.97 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:ACHN' s Equity-to-Asset Range Over the Past 10 Years
Min: -6.98  Med: 0.71 Max: 0.97
Current: 0.97
-6.98
0.97
Piotroski F-Score: 1
Altman Z-Score: 22.81
Beneish M-Score: 179.91
WACC vs ROIC
18.46%
-3362.62%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -432.43
NAS:ACHN's Operating Margin % is ranked lower than
69% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. NAS:ACHN: -432.43 )
Ranked among companies with meaningful Operating Margin % only.
NAS:ACHN' s Operating Margin % Range Over the Past 10 Years
Min: -17954.25  Med: -594.6 Max: 11879.49
Current: -432.43
-17954.25
11879.49
Net Margin % -411.37
NAS:ACHN's Net Margin % is ranked lower than
68% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. NAS:ACHN: -411.37 )
Ranked among companies with meaningful Net Margin % only.
NAS:ACHN' s Net Margin % Range Over the Past 10 Years
Min: -17897.17  Med: -553.66 Max: 12030.34
Current: -411.37
-17897.17
12030.34
ROE % -14.66
NAS:ACHN's ROE % is ranked higher than
64% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. NAS:ACHN: -14.66 )
Ranked among companies with meaningful ROE % only.
NAS:ACHN' s ROE % Range Over the Past 10 Years
Min: -199.15  Med: -69.33 Max: -1.7
Current: -14.66
-199.15
-1.7
ROA % -14.19
NAS:ACHN's ROA % is ranked higher than
65% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. NAS:ACHN: -14.19 )
Ranked among companies with meaningful ROA % only.
NAS:ACHN' s ROA % Range Over the Past 10 Years
Min: -103.25  Med: -56.05 Max: -1.62
Current: -14.19
-103.25
-1.62
ROC (Joel Greenblatt) % -1634.87
NAS:ACHN's ROC (Joel Greenblatt) % is ranked lower than
69% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. NAS:ACHN: -1634.87 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:ACHN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -6041.18  Med: -2833.51 Max: -287.49
Current: -1634.87
-6041.18
-287.49
3-Year EBITDA Growth Rate -10.60
NAS:ACHN's 3-Year EBITDA Growth Rate is ranked lower than
63% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. NAS:ACHN: -10.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:ACHN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -41.2 Max: 4.5
Current: -10.6
0
4.5
3-Year EPS without NRI Growth Rate -10.60
NAS:ACHN's 3-Year EPS without NRI Growth Rate is ranked lower than
61% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. NAS:ACHN: -10.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:ACHN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -65.5  Med: -26.6 Max: 3.4
Current: -10.6
-65.5
3.4
GuruFocus has detected 2 Warning Signs with Achillion Pharmaceuticals Inc $NAS:ACHN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ACHN's 10-Y Financials

Financials (Next Earnings Date: 2017-08-04 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ACHN Guru Trades in Q1 2016

Joel Greenblatt 554,125 sh (New)
Paul Tudor Jones 39,959 sh (New)
Steven Cohen 9,103,921 sh (+1.53%)
Jim Simons Sold Out
» More
Q2 2016

ACHN Guru Trades in Q2 2016

Steven Cohen 8,987,615 sh (-1.28%)
Paul Tudor Jones 19,846 sh (-50.33%)
Joel Greenblatt 191,792 sh (-65.39%)
» More
Q3 2016

ACHN Guru Trades in Q3 2016

Jim Simons 552,600 sh (New)
Paul Tudor Jones 102,612 sh (+417.04%)
Joel Greenblatt Sold Out
Steven Cohen 7,054,346 sh (-21.51%)
» More
Q4 2016

ACHN Guru Trades in Q4 2016

Paul Tudor Jones 195,149 sh (+90.18%)
Jim Simons 945,189 sh (+71.04%)
Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ACHN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:NTLA, NAS:ANAB, NAS:ATRA, NAS:WVE, OTCPK:SNBIF, NAS:RARX, NAS:ADAP, NAS:LJPC, NAS:BCRX, NAS:BYSI, NAS:NLNK, NAS:INO, NAS:PRTK, NAS:RETA, NAS:CARA, NAS:ITCI, OTCPK:SPHDF, NAS:PGNX, NAS:ACIU, NAS:IMMU » details
Traded in other countries:ADA.Germany,
Headquarter Location:USA
Achillion Pharmaceuticals Inc is a biopharmaceutical company which focuses on the discovery, development and commercialization of treatments for infectious diseases like hepatitis C virus, or HCV, infection that are once-daily and ribavirin-free.

Achillion Pharmaceuticals is a biotechnology company that seeks to discover and commercialize treatments for rare diseases. The company is engaged solely in the discovery and development of innovative small-molecule drug therapies for infectious diseases and immune system disorders. Achillion specializes in structural biology, medicinal chemistry, and antimicrobial discovery research. The company generates revenue from product sales, regulatory and commercialization milestones, and royalties. Achillion also uses collaborative and licensing agreements.

Ratios

vs
industry
vs
history
PB Ratio 1.15
ACHN's PB Ratio is ranked higher than
83% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. ACHN: 1.15 )
Ranked among companies with meaningful PB Ratio only.
ACHN' s PB Ratio Range Over the Past 10 Years
Min: 0.79  Med: 3.51 Max: 12.16
Current: 1.15
0.79
12.16
PS Ratio 31.00
ACHN's PS Ratio is ranked lower than
74% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. ACHN: 31.00 )
Ranked among companies with meaningful PS Ratio only.
ACHN' s PS Ratio Range Over the Past 10 Years
Min: 0.84  Med: 216.92 Max: 7995
Current: 31
0.84
7995
EV-to-EBIT -2.96
ACHN's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. ACHN: -2.96 )
Ranked among companies with meaningful EV-to-EBIT only.
ACHN' s EV-to-EBIT Range Over the Past 10 Years
Min: -213.5  Med: -3.6 Max: 132.9
Current: -2.96
-213.5
132.9
EV-to-EBITDA -3.00
ACHN's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. ACHN: -3.00 )
Ranked among companies with meaningful EV-to-EBITDA only.
ACHN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -264.5  Med: -3.7 Max: 118.7
Current: -3
-264.5
118.7
Current Ratio 27.38
ACHN's Current Ratio is ranked higher than
96% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. ACHN: 27.38 )
Ranked among companies with meaningful Current Ratio only.
ACHN' s Current Ratio Range Over the Past 10 Years
Min: 1.06  Med: 6.16 Max: 31.56
Current: 27.38
1.06
31.56
Quick Ratio 27.38
ACHN's Quick Ratio is ranked higher than
96% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. ACHN: 27.38 )
Ranked among companies with meaningful Quick Ratio only.
ACHN' s Quick Ratio Range Over the Past 10 Years
Min: 1.06  Med: 6.16 Max: 31.56
Current: 27.38
1.06
31.56
Days Sales Outstanding 371.23
ACHN's Days Sales Outstanding is ranked lower than
97% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. ACHN: 371.23 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACHN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.79  Med: 124.65 Max: 371.23
Current: 371.23
2.79
371.23

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -12.20
ACHN's 3-Year Average Share Buyback Ratio is ranked lower than
53% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. ACHN: -12.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ACHN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -274.8  Med: -35.85 Max: -12.2
Current: -12.2
-274.8
-12.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 1.33
ACHN's Price-to-Net-Cash is ranked higher than
91% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. ACHN: 1.33 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ACHN' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.82  Med: 4.85 Max: 12.7
Current: 1.33
0.82
12.7
Price-to-Net-Current-Asset-Value 1.27
ACHN's Price-to-Net-Current-Asset-Value is ranked higher than
91% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. ACHN: 1.27 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ACHN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.78  Med: 4.52 Max: 12.29
Current: 1.27
0.78
12.29
Price-to-Tangible-Book 1.17
ACHN's Price-to-Tangible-Book is ranked higher than
88% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. ACHN: 1.17 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ACHN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.72  Med: 4.79 Max: 81.84
Current: 1.17
0.72
81.84
Price-to-Median-PS-Value 0.14
ACHN's Price-to-Median-PS-Value is ranked higher than
93% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. ACHN: 0.14 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ACHN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.01  Med: 0.26 Max: 8.76
Current: 0.14
0.01
8.76
Earnings Yield (Greenblatt) % -33.97
ACHN's Earnings Yield (Greenblatt) % is ranked lower than
83% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. ACHN: -33.97 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ACHN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -43.6  Med: 275.7 Max: 15068.8
Current: -33.97
-43.6
15068.8

More Statistics

Revenue (TTM) (Mil) $15.00
EPS (TTM) $ -0.45
Beta2.71
Short Percentage of Float8.66%
52-Week Range $3.15 - 10.06
Shares Outstanding (Mil)136.72

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 38 260 25
EPS ($) -0.13 1.63 -0.07
EPS without NRI ($) -0.13 1.63 -0.07
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:ACHN

Headlines

Articles On GuruFocus.com
Achillion Announces Additional Phase 2 Results Including 100% SVR24 for Genotype 1 HCV After 6-Weeks Apr 22 2017 
Achillion Announces Initiation of Patient Dosing in Phase 2 Study of ACH-4471 for Paroxysmal Nocturn Apr 06 2017 
USPTO Grants Composition of Matter Patent to Achillion for Small Molecule Complement Alternative Pat Mar 21 2017 
Steven Cohen Increases Position in Dynavax Oct 07 2016 
UBS and JMP Securities Downgrade Achillion Pharmaceuticals Inc.(ACHN) Following Johnson & Johnson (J May 21 2015 
Dycom Industries (DY) Surpasses Estimates; Achillion Pharma (ACHN) Inks Mega-Deal with Janssen May 20 2015 
Gilead Experiencing Bumpy Ride Despite Strong Fundamentals Apr 03 2015 
Achillion Pharmaceuticals Stock Soars Following Successful Mid-Stage Hep C Drug Combo Trial Feb 10 2015 
Hall of Fame/ Hall of Shame: The Best and Worst Recommendations of 2014 Jan 09 2015 
Weekly CEO Sells Highlight: Achillion Pharmaceutical Inc, Protective Life Corp, Host Hotels & Resort Aug 25 2014 

More From Other Websites
ETFs with exposure to Achillion Pharmaceuticals, Inc. : April 25, 2017 Apr 25 2017
Why Achillion Pharmaceuticals Stock Sank on Monday Apr 25 2017
Today's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and XOMA Apr 25 2017
Why Achillion Pharmaceuticals, Noble Corp., and RLJ Lodging Trust Slumped Today Apr 24 2017
Achillion Announces Additional Phase 2 Results Including 100% SVR24 for Genotype 1 HCV After 6-Weeks... Apr 22 2017
If You Don't Buy These 5 Stocks Before Their Looming Breakout, It's Your Loss Apr 20 2017
Achillion Announces Initiation of Patient Dosing in Phase 2 Study of ACH-4471 for Paroxysmal... Apr 06 2017
Today's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and Corbus Pharmaceuticals Mar 31 2017
Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US :... Mar 30 2017
Why Is Achillion (ACHN) Down 11.3% Since the Last Earnings Report? Mar 28 2017
USPTO Grants Composition of Matter Patent to Achillion for Small Molecule Complement Alternative... Mar 21 2017
Achillion Pharmaceuticals, Inc. :ACHN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017 Mar 07 2017
Celldex Therapeutics (CLDX) Q4 Earnings: What's in Store? Mar 06 2017
These 5 Stocks Under $10 Could Explode Up Soon Mar 02 2017
Achillion Pharmaceuticals to Support a Natural History Study of C3 Glomerulopathy, a Rare Renal... Feb 28 2017
Achillion (ACHN) Reports Narrower-Than-Expected Q4 Loss Feb 27 2017
Biotech Movers: Cempra Flys High On Phase Three Results Feb 24 2017
Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US :... Feb 24 2017
Achillion reports 4Q loss Feb 23 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)